Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Románia4. fázis

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

A legfontosabb adatok

Ki végzi
RECORDATI GROUP
Hol
Bucharest, Cluj-Napoca, Târgu Mureş és Timisoara (Románia)Mind a 4 helyszín megnézéseMég 7 másik országban, 36 helyszínen
Állapot
Toboroz
Fázis
4. fázis
Résztvevők
63 fő, tervezett
Kezdés
2026. aug. 26.
Várható befejezés
2028. júl.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Osilodrostat
  • Placebo
A regiszteradat frissítve
2026. november 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with endogenous Cushing's syndrome (the body makes too much cortisol) who have high blood pressure not controlled by their medicines.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
Endogenous Cushing's syndrome with uncontrolled high blood pressure. Average 24h ambulatory blood pressure must be SBP ≥ 135 or DBP ≥ 85 mmHg.
Korábbi kezelés
Blood pressure medicines at stable doses for at least 4 weeks. No drug therapy for Cushing's syndrome, with set breaks before the study (e.g. ketoconazole, metyrapone 1 week; Mifepristone 3 weeks; SC Pasireotide 1 week; Pasireotide LAR 3 months; Cabergoline 4 weeks). Glucocorticoid replacement stopped for at least seven days or 5 half-lives. No osilodrostat in the 12 weeks before screening. No prior mitotane.
Biomarker vagy leletérték
Urine cortisol (mUFC) from two 24h urine collections above the upper normal limit and at most 2x the upper normal limit.

A részvétel fő kizáró okai

  • Surgery for Cushing's syndrome planned within 32 weeks, or pituitary or adrenal surgery within 3 months before screening
  • Pituitary radiation within 3 years, or cyclic or pseudo-Cushing's syndrome
  • Tumour pressing on or within 2 mm of the optic nerve crossing
  • Poorly controlled diabetes with HbA1c > 10.5% (91 mmol/mol)
  • Pregnant or breastfeeding, or shift workers

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female ≥ 18 years of age
  • Able to provide and have provided signed written informed consent prior to study participation
  • Diagnosis of endogenous Cushing's Syndrome
  • mUFC values from two 24h urinary collections > ULN and ≤ 2x ULN
  • Participants with uncontrolled hypertension on stable doses of BP lowering medications (for at least 4 weeks); qualifying BP measurements by ABPM taken prior to randomisation defined as: Average of 24h ABPM SBP ≥ 135 or DBP ≥ 85 mmHg
  • Participants under glucocorticoid replacement therapy can be recruited only if this therapy has been already stopped for at least seven days or 5 half-lives prior to screening, whichever was longer
  • Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments:; Steroidogenesis inhibitors (e.g. ketoconazole, metyrapone): 1 week; Mifepristone: 3 weeks; SC Pasireotide: 1 week; Pasireotide LAR: 3 months; Cabergoline: 4 weeks
  • Able to take oral medication and be willing to comply with the requirements of the study

Ki nem vehet részt

  • Previously treated with osilodrostat less than 12 weeks prior to start of screening
  • Participants who are scheduled for a surgery to treat CS within 32 weeks of randomisation to the study drug
  • Presence of a known "long term" history of both hypertension and diabetes (defined as both hypertension and diabetes diagnosed >10 years prior to the initial diagnosis of endogenous CS)
  • Participants who have undergone pituitary or adrenal surgery for Cushing's syndrome within 3 months prior to screening
  • Pituitary radiation therapy within 3 years of screening
  • Ectopic ACTH syndrome or adrenocortical carcinoma with a life expectancy of <3 years or receiving chemotherapy
  • Having received prior mitotane treatment
  • Participants who are hypothyroid and not on adequate replacement therapy
  • History of major surgery/surgical therapy for any cause within 4 weeks before entering the study. Participants should have recovered from the surgery and be in good clinical condition before entering the study
  • Participation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an investigational drug within 4 weeks prior to dosing)
  • Occurrence of any significant acute illness within 3 weeks prior to dosing/randomisation
  • Known hypersensitivity to osilodrostat
  • Presence of any severe and/or uncontrolled medical condition or other conditions that could affect participation in the study
  • History of cyclic CS with fluctuating clinical manifestations
  • Participants who are shift workers or have conditions that can affect the measurement of late-night salivary cortisol (LNSC) or the LDDST
  • Poorly controlled diabetes mellitus with a baseline HbA1c > 10.5%. Participants receiving glucose lowering medications must be on stable doses for at least 4 weeks prior screening
  • Presence of bradycardia and/or QT-related exclusion criteria
  • Total bilirubin > 1.5 x ULN and ALT or AST > 3 x ULN
  • Female participants who are pregnant, intending to become pregnant or breastfeed during the study or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  • Participants with pseudo-CS
  • Participants with compression of the optic chiasm due to a macroadenoma or participants at high risk of compression of the optic chiasm (tumour within 2 mm of optic chiasm)
  • Women of childbearing potential (WOCBP) who are unwilling to use highly effective contraception methods
  • Potentially unreliable or vulnerable participants (e.g. person kept in detention) and those judged by the Investigator to be unsuitable for the study

Helyszínek itt: Románia

Még 7 másik országban, 36 helyszínen

  • National Institute Of Endocrinology C.I. ParhonBucharest, RomániaRésztvevőt keres
  • Spitalul Clinic Judetean De Urgenta ClujCluj-Napoca, RomániaRésztvevőt keres
  • Spitalul Clinic Judetean de Urgenta Targu MuresTârgu Mureş, RomániaRésztvevőt keres
  • Spitalul Clinic Judetean De Urgenta Pius Brinzeu TimisoaraTimisoara, RomániaRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.

A vizsgálat 2 csoportja

  • LCI699 (osilodrostat)A vizsgált kezelés

    1 mg QOD

    Kezelés: Osilodrostat

  • PlaceboPlacebo, összehasonlításként

    matching placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Double-blind, Randomised, 30-week Placebo-controlled Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. november 2.